Carving Out a Role for Cyclin E1 in Platinum-Resistant Ovarian Cancer

Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.

Dr O’Malley discusses his approach to treatment selection and sequencing in platinum-resistant ovarian cancer.

David O’Malley, MD, discusses how ADCs have redefined the treatment paradigm in platinum-resistant ovarian cancer.

Premal Thaker, MD, MS, discusses the role for CDK2 inhibition in platinum-resistant ovarian cancer.

Premal H. Thaker, MD, MS, discusses the phase 2 MAESTRA 1 trial (NCT07023627) in platinum-resistant ovarian cancer.